We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Mirum Pharmaceuticals (MIRM) Down 3.6% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Mirum Pharmaceuticals, Inc. (MIRM - Free Report) . Shares have lost about 3.6% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Mirum Pharmaceuticals due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Mirum reported a loss of 11 cents per share in the fourth quarter of 2025 against the Zacks Consensus Estimate of earnings of 2 cents. The company has incurred a loss of 49 cents per share in the year-ago quarter.
Revenues in the fourth quarter totaled $148.9 million, up 50.5% year over year. The figure also beat the Zacks Consensus Estimate of $141 million. The top line was driven by the strong growth of Livmarli and recently acquired bile acid medicines, Cholbam and Ctexli.
Quarter in Detail
During the fourth quarter, the company did not record any license and other revenues.
Research and development expenses increased almost 16.1% year over year to $51.1 million.
Selling, general and administrative expenses totaled $74.1 million, up almost 30.5% from the year-ago quarter’s level.
As of Dec. 31, 2025, Mirum had cash, cash equivalents and investments worth $391.4 million compared with $378 million as of Sept. 30. 2025.
2026 Guidance
Mirum expects worldwide net product sales of approximately $630-$650 million in 2026. The company expects to return to positive cash flow in 2027.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended downward during the past month.
The consensus estimate has shifted -895.83% due to these changes.
VGM Scores
Currently, Mirum Pharmaceuticals has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock has a score of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Mirum Pharmaceuticals has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Mirum Pharmaceuticals belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Royalty Pharma (RPRX - Free Report) , has gained 3.5% over the past month. More than a month has passed since the company reported results for the quarter ended December 2025.
Royalty Pharma reported revenues of $874 million in the last reported quarter, representing a year-over-year change of +17.8%. EPS of $1.46 for the same period compares with $1.15 a year ago.
Royalty Pharma is expected to post earnings of $1.18 per share for the current quarter, representing a year-over-year change of +11.3%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.4%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Royalty Pharma. Also, the stock has a VGM Score of C.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Why Is Mirum Pharmaceuticals (MIRM) Down 3.6% Since Last Earnings Report?
It has been about a month since the last earnings report for Mirum Pharmaceuticals, Inc. (MIRM - Free Report) . Shares have lost about 3.6% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Mirum Pharmaceuticals due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues
Mirum reported a loss of 11 cents per share in the fourth quarter of 2025 against the Zacks Consensus Estimate of earnings of 2 cents. The company has incurred a loss of 49 cents per share in the year-ago quarter.
Revenues in the fourth quarter totaled $148.9 million, up 50.5% year over year. The figure also beat the Zacks Consensus Estimate of $141 million. The top line was driven by the strong growth of Livmarli and recently acquired bile acid medicines, Cholbam and Ctexli.
Quarter in Detail
During the fourth quarter, the company did not record any license and other revenues.
Research and development expenses increased almost 16.1% year over year to $51.1 million.
Selling, general and administrative expenses totaled $74.1 million, up almost 30.5% from the year-ago quarter’s level.
As of Dec. 31, 2025, Mirum had cash, cash equivalents and investments worth $391.4 million compared with $378 million as of Sept. 30. 2025.
2026 Guidance
Mirum expects worldwide net product sales of approximately $630-$650 million in 2026. The company expects to return to positive cash flow in 2027.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended downward during the past month.
The consensus estimate has shifted -895.83% due to these changes.
VGM Scores
Currently, Mirum Pharmaceuticals has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock has a score of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Mirum Pharmaceuticals has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Mirum Pharmaceuticals belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Royalty Pharma (RPRX - Free Report) , has gained 3.5% over the past month. More than a month has passed since the company reported results for the quarter ended December 2025.
Royalty Pharma reported revenues of $874 million in the last reported quarter, representing a year-over-year change of +17.8%. EPS of $1.46 for the same period compares with $1.15 a year ago.
Royalty Pharma is expected to post earnings of $1.18 per share for the current quarter, representing a year-over-year change of +11.3%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.4%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Royalty Pharma. Also, the stock has a VGM Score of C.